This development is the first and only FDA approved diagnostic test kit for parvovirus B19. Parvovirus B19 infection in pregnancy is often overlooked simply because most infected pregnant women are asymptomatic or have only mild manifestations, such as slight itching. However, pregnant women (in the first and second trimesters) with the B19 infection can give rise to serious fetal complications during pregnancy. Up to 50% of women are susceptible to parvovirus B19 infection. The B19 infection may result in anemia, pregnancy miscarriage and/or other problems. Early diagnosis of B19V infection will identify those at risk and may allow for early intervention therapy, thereby improving fetal survival. Patients who are immuno-compromised and others may also develop chronic B19 infection that previously has been difficult to diagnose. This new test kit will make diagnosis much easier and more reliable. 

Awardees

National Heart Lung and Blood Institute 

• Dr. Neal Young 
• Dr. Sachiko Kajigaya